JLE

Néphrologie & Thérapeutique

MENU

Cardiovascular calcifications in dialysis patients Volume 19, issue 6, October 2023

Authors
1 Chef de service de dialyse de l’AURA Nord, Saint-Ouen ; Hôpital Bichat, 12, rue Anselme, 93400 Saint-Ouen, France
2 Hôpital Necker, Service des explorations fonctionnelles rénales, Université Paris Descartes, Paris, France
3 Directeur médical, AURA Paris, Ivry-Sur-Seine, France
Correspondance : P. Ureña Torres
pablo.urena@auraparis.org

Patients with advanced chronic kidney disease and those already on dialysis have an increased prevalence of cardiovascular calcifications. They are the cause of severe complications and are associated with a reduced life expectancy in these patients. Recommendations and imaging scores have been developed to detect and assess their importance, to guide and improve the management of cardiovascular risk. However, despite these recommendations, current practice teaches us that they are only partially applied. The prevention and treatment of cardiovascular calcifications go through the correction of classic risk factors associated with atherosclerosis, mineral and bone metabolism disorders and by optimizing the dose and the efficiency of dialysis. New therapeutic strategies are beginning to emerge, others are being evaluated, such as sodium thiosulfate, rheopheresis, vitamin K, magnesium supplementation, and SNF-472.